Related Experiment Video

Updated: Aug 20, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.9K

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease

Fabrizio Fabrizi1, Federica Tripodi1, Roberta Cerutti1

  • 1Division of Nephrology, Dialysis, and Kidney Transplant, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.

Viruses
|November 24, 2022
PubMed

Insights

Direct-acting antiviral drugs (DAAs) are effective and safe for treating Hepatitis C virus (HCV) in patients with advanced chronic kidney disease (CKD). These pan-genotypic treatments offer high sustained virologic response rates, improving outcomes for this vulnerable population.

Area of Science:

  • Nephrology
  • Hepatology
  • Virology

Background:

  • Chronic Hepatitis C virus (HCV) infection is a significant risk factor for the increased incidence of chronic kidney disease (CKD) in adults.
  • A meta-analysis of over 2 million patients confirmed a 54% increased risk of CKD in those with positive anti-HCV status.

Purpose of the Study:

  • To review the efficacy and safety of pan-genotypic direct-acting antiviral (DAA) therapies for Hepatitis C virus (HCV) in patients with advanced chronic kidney disease (CKD stage 4/5).

Main Methods:

  • A narrative review of studies was conducted using electronic databases and grey literature.
  • Keywords included 'Hepatitis C', 'Chronic kidney disease', and 'Pan-genotypic agents' to identify relevant research.
  • Data from clinical trials and real-world studies were synthesized to evaluate treatment outcomes.

Main Results:

  • Glecaprevir/pibrentasvir (GLE/PIB) demonstrated sustained virologic response 12 (SVR12) rates of 86-99% in advanced CKD.
  • Sofosbuvir/velpatasvir (SOF/VEL) achieved a pooled SVR rate of 100% in studies involving patients with advanced CKD.
  • Adverse event-related dropout rates for SOF/VEL were low, ranging from 0 to 4.8%.

Conclusions:

  • Pan-genotypic DAAs, specifically GLE/PIB and SOF/VEL, are effective and safe options for treating HCV in patients with advanced CKD.
  • While current evidence is based on limited studies with small sample sizes, these treatments show promising results.
  • Further research is ongoing to determine if successful DAA therapy improves long-term survival in patients with advanced CKD.
Abstract

Keywords:
dialysisend-stage kidney diseasehepatitis C virussofosbuvirsustained viral response

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.3K

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
54
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
60
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
738
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
40
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
70
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
53